Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma

Haematologica. 2002 Jul;87(7):779-81.

Abstract

We report that early chemosensitivity, defined by a greater than 50% reduction of M-component and plasma-cell marrow infiltration, after 2 cycles of VAD was correlated with a favorable outcome following autologous stem cell transplantation in 46 patients with newly diagnosed multiple myeloma submitted to high-dose therapy.

Publication types

  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cytarabine / administration & dosage
  • Dexamethasone / administration & dosage
  • Humans
  • Multiple Myeloma / diagnosis
  • Multiple Myeloma / mortality*
  • Multiple Myeloma / therapy*
  • Prognosis
  • Retrospective Studies
  • Stem Cell Transplantation*
  • Survival Analysis
  • Time Factors
  • Transplantation, Autologous
  • Treatment Outcome
  • Vincristine / administration & dosage

Substances

  • Cytarabine
  • Vincristine
  • Dexamethasone

Supplementary concepts

  • VAD regimen